Metabolic and cardiovascular profiles in diabetes type 2: a comparative analysis of zinc homeostasis and blood pressure—a single center case–control study Authors: Sara M. Eladawy, Heba H. Salem, Gehan F. Balata, Ahmed A. Abdelkader, Mohamed Hany Abdelraouf, Ahmed Mostafa Abdelazem, Mohamed Khaled Ahmed Awad, Shams Abdo Mostafa Hassan, Mohamed Saad Rady Attallah, Merna Magdy Zakaria, Nada Mohamed Sayed Rateb, Aml Abdel Aziz Mohamed Zidan, Nada Elrekawky Helmy Tawfik, Sara Soliman Mousa, Tasnem Ahmed Ali, Maryam Khaled Attia Mohamed, Mariam Ashraf Abdo, Asmaa Mohamed Hassan, Eslam Sobhy Abdelaziz, Kholud Ashraf Mohamed, Hedra Asad Thabet, Rewan Tarek Muhamed, Dina Hassan El Sayed, Nancy Essam El Hussaini Mohamed, Abdel Rahman Mohamed Hashem, Mariam Khaled Mohamed, David Magdy Maurice Gendi, Sara Alaa Eldin Essam, Mark Alkes Rezkalla Nouh, Hala Esameldin Mohamed Kahla, Shereen Sadik El Sway, Rasha Sobh Mohamed Farag, Bassant Saeed Gaber, Amal Ahmed Mohamed, Mohamed Said Mahmoud, Naglaa Fawzy, Amira Mohamed Fadl, Ali Mahmoud Abdelkader, Hany N. Azzam Published: 2026 ABSTRACT Zinc plays an important role in glucose metabolism and lipid regulation, and its imbalance has been implicated in the development of type 2 diabetes, metabolic syndrome, and dyslipidemia. A case–control study was conducted on 100 patients with type 2 diabetes and 95 controls. Serum zinc levels, metabolic panel and Blood pressure, were measured. Demographic and treatment-related factors were assessed to evaluate their potential influence on trace element status. Moreover, dietary zinc consumption was estimated. Diabetic patients had significantly lower serum zinc levels compared to non-diabetic participants despite comparable intake. In addition, each unit (mcg/dL) increase in serum zinc was associated with 10% lower odds of diabetes prevalence (p = 0.003). Total TC, TG, and LDL were all significantly increased in patients with diabetes (p < 0.001), each 1 mg/dL increase in LDL-cholesterol increased the odds of zinc deficiency by 4% (p = 0.03). Individuals with diabetes had significantly lower diastolic blood pressure as compared to healthy participants (p = 0.01). People with diabetes display different blood pressure and lipid patterns, as well as lower serum zinc concentrations, despite having dietary zinc intake comparable to those without diabetes. Higher serum zinc levels are associated with reduced odds of having diabetes. However, because these findings are based on cross-sectional data, further longitudinal and intervention studies are needed to determine the most effective zinc formulations and dosing regimens. Introduction According to recent data published in The Lancet on World Diabetes Day, the number of adults with diabetes has more than quadrupled since 1990, surpassing 800 million people globally1. The World Health Organization (WHO)-supported Chronic Non-Communicable Diseases (NCD) Risk Factor Collaboration (NCD-RisC) conducted the analysis, which emphasizes the scope of the diabetes epidemic and the pressing need for more robust international action to address both growing disease rates and expanding treatment gaps, especially in low- and middle-income countries (LMICs)1. Diabetes is a rapidly expanding health issue in Egypt that has a major effect on health care resources, morbidity, and death. Approximately 15.6% of adults between the ages of 20 and 79 in Egypt now have type 2 diabetes (T2D)2. Additionally, the total cost of diabetes was estimated to be EGP 25.2 billion that is equivalent to USD 3.5 billion. About EGP 22.3 billion was spent on direct medical care, of which the largest portion, EGP 14.4 billion (65%), was directed toward managing DM complications3. Therefore, it presents a significant health issue as well as a substantial financial burden. Zinc is an important trace metal that plays a key role in the production, storage, and release of insulin by the pancreas4. Rises in oxidative stress, especially in pancreatic β-cells, and changes in trace element levels, including zinc, have been noted in people with diabetes mellitus. In peripheral tissues like muscle, adipose tissues, and the liver, these imbalances might aggravate insulin resistance, impairing glycemic control and increasing the risk of diabetic complications. In turn, the overall status of zinc and other trace minerals may worsen as diabetes progresses5. Insulin resistance, a defining feature of T2D, has been observed in association with low zinc levels, which may be linked to alterations in the pancreas’s capacity to produce and secrete insulin as well as peripheral cells’ ability to absorb glucose, though causality has not been established6. Two main mechanisms have been proposed for the zinc deficiency seen in people with diabetes mellitus. The first mechanism relates to decreased intestinal absorption of this vital micronutrient as a result of diabetes-related gastrointestinal changes and impairment in zinc transport mechanisms. Additionally, increased urinary excretion of zinc where hyperglycemia and related metabolic disturbances in diabetes can lead to increased urinary loss of zinc, further exacerbating the deficiency4. The observed relationship between diabetes mellitus and trace element dysregulation highlights the importance of maintaining adequate micronutrient status. Further research is needed to evaluate whether addressing these dietary imbalances may contribute to improved glycemic control and reduced risk of diabetic complications7. Accordingly, the current study aimed to compare zinc homeostasis and blood pressure between type 2 diabetes patients and non-diabetic controls and to investigate the association between serum zinc level and its daily consumption and diabetes. Methodology Study design and ethical approval This study is a Case–control study that was registered on clinical trial.gov (ClinicalTrials.gov Identifier: NCT06751823). The study received ethical approval from the Institutional Research Ethics Committee at Heliopolis University (Approval No.: HU.REC.H9-2024), and written informed consent was obtained from all participants. All experiments were performed in accordance with relevant guidelines and regulations. Study participants The sample size was determined based on the difference in mean serum zinc level in a previous study essential trace elements and their association with type 2 diabetes mellitus, with 62.89 ± 30.67 µg/dL in patients with T2DM and 74.95 ± 18.11 µg/dL in healthy participants8. With 90% power and an alpha level of 0.05, the minimum required sample size to detect this effect was 186 participants (1:1 ratio) using G*Power software version 3.1.9.79. Participants were divided into two groups; the first group comprised 100 patients with T2D and the second control group included 95 healthy participants. Diabetic patients were recruited from the outpatient internal medicine, diabetes and endocrinology clinics of Kasr Alaini Hospital School of Medicine (Cairo University), Cairo, Egypt. Control participants were recruited from the same hospital setting, among individuals accompanying patients to outpatient visits. Controls were confirmed to be free of diabetes and pre-diabetes based on fasting blood glucose < 100 mg/dL and HbA1c < 5.7%, in accordance with the American Diabetes Association diagnostic criteria10. Confirmed cases of T2D patients of more than 40 years old were considered eligible for the study irrespective of sex, religion, socio economic status, duration of diabetes and treatment. Exclusion criteria were as follows: pregnant or lactating women, type 1 diabetic patients as well as diabetic patients with known malignancy, chronic kidney, liver, cardiovascular diseases or with any other endocrinological disorders. In addition, patients were excluded from the study if they were administering any drugs affecting electrolytes (including Mg-containing laxatives), vitamin and/or mineral supplements, thyroid hormones, estrogen, progesterone, diuretics, antihypertensive agents, or psychiatric & antidepressant drugs. Data collection A written informed consent has been obtained from all subjects.A socio‑demographic profile: such as age, sex, Body Mass Index (BMI), smoking habit, physical examination and blood pressure of all participants as well as duration of diabetes and medications of patients with diabetes were recorded.Biochemical analysis: Blood samples (3–5 ml) were collected, centrifuged for 10 min at 4000 rpm at 4 °C and serum was separated and stored at − 80°C till further analysis. Estimations of Fasting blood glucose, glycated haemoglobin (HbA1c), lipid profile and kidney function have been done.Elemental analysis: The concentration of serum zinc was quantitatively determined using a 5-Bromo-PAPS-based colorimetric assay kit supplied by (Spectrum Diagnostics, Cairo, Egypt) on a Roche Cobas c501 automated analyzer (Roche Diagnostics, Germany). Zinc ions in serum samples react with 2-(5-Bromo-2-pyridylazo)-5-(N-propyl-N-sulphopropylamino)-phenol to form a colored chelate complex measured by endpoint spectrophotometry at 546 nm, with absorbances being directly proportional to zinc concentration11.Dietary Zinc consumption estimation: dietary zinc intake was estimated using a validated semi-quantitative food frequency questionnaire developed for screening the micronutrient intake of economically active adults12. Although this instrument was originally designed for a South African population, it was selected because it captures 30 food items representing the major sources of key micronutrients, including zinc, many of which are common to the Egyptian dietary pattern. The questionnaire was reviewed for cultural appropriateness and content validity by experts in pharmacy practice and nutrition prior to data collection and was translated. Moreover, a pilot study including 10–12 individuals has been performed to confirm clarity and ease of completion. Zinc intake was calculated using the equation [∑ (zinc content in food (µg/kg) × food intake (g/day) / 1000)], as previously described13,14. Individual zinc intake was compared to the age- and sex-specific Recommended Dietary Allowance using the DRI Calculator for Healthcare Professionals15. A written informed consent has been obtained from all subjects. A written informed consent has been obtained from all subjects. A socio‑demographic profile: such as age, sex, Body Mass Index (BMI), smoking habit, physical examination and blood pressure of all participants as well as duration of diabetes and medications of patients with diabetes were recorded. A socio‑demographic profile: such as age, sex, Body Mass Index (BMI), smoking habit, physical examination and blood pressure of all participants as well as duration of diabetes and medications of patients with diabetes were recorded. Biochemical analysis: Blood samples (3–5 ml) were collected, centrifuged for 10 min at 4000 rpm at 4 °C and serum was separated and stored at − 80°C till further analysis. Estimations of Fasting blood glucose, glycated haemoglobin (HbA1c), lipid profile and kidney function have been done. Biochemical analysis: Blood samples (3–5 ml) were collected, centrifuged for 10 min at 4000 rpm at 4 °C and serum was separated and stored at − 80°C till further analysis. Estimations of Fasting blood glucose, glycated haemoglobin (HbA1c), lipid profile and kidney function have been done. Elemental analysis: The concentration of serum zinc was quantitatively determined using a 5-Bromo-PAPS-based colorimetric assay kit supplied by (Spectrum Diagnostics, Cairo, Egypt) on a Roche Cobas c501 automated analyzer (Roche Diagnostics, Germany). Zinc ions in serum samples react with 2-(5-Bromo-2-pyridylazo)-5-(N-propyl-N-sulphopropylamino)-phenol to form a colored chelate complex measured by endpoint spectrophotometry at 546 nm, with absorbances being directly proportional to zinc concentration11. Elemental analysis: The concentration of serum zinc was quantitatively determined using a 5-Bromo-PAPS-based colorimetric assay kit supplied by (Spectrum Diagnostics, Cairo, Egypt) on a Roche Cobas c501 automated analyzer (Roche Diagnostics, Germany). Zinc ions in serum samples react with 2-(5-Bromo-2-pyridylazo)-5-(N-propyl-N-sulphopropylamino)-phenol to form a colored chelate complex measured by endpoint spectrophotometry at 546 nm, with absorbances being directly proportional to zinc concentration11. Dietary Zinc consumption estimation: dietary zinc intake was estimated using a validated semi-quantitative food frequency questionnaire developed for screening the micronutrient intake of economically active adults12. Although this instrument was originally designed for a South African population, it was selected because it captures 30 food items representing the major sources of key micronutrients, including zinc, many of which are common to the Egyptian dietary pattern. The questionnaire was reviewed for cultural appropriateness and content validity by experts in pharmacy practice and nutrition prior to data collection and was translated. Moreover, a pilot study including 10–12 individuals has been performed to confirm clarity and ease of completion. Zinc intake was calculated using the equation [∑ (zinc content in food (µg/kg) × food intake (g/day) / 1000)], as previously described13,14. Individual zinc intake was compared to the age- and sex-specific Recommended Dietary Allowance using the DRI Calculator for Healthcare Professionals15. Dietary Zinc consumption estimation: dietary zinc intake was estimated using a validated semi-quantitative food frequency questionnaire developed for screening the micronutrient intake of economically active adults12. Although this instrument was originally designed for a South African population, it was selected because it captures 30 food items representing the major sources of key micronutrients, including zinc, many of which are common to the Egyptian dietary pattern. The questionnaire was reviewed for cultural appropriateness and content validity by experts in pharmacy practice and nutrition prior to data collection and was translated. Moreover, a pilot study including 10–12 individuals has been performed to confirm clarity and ease of completion. Zinc intake was calculated using the equation [∑ (zinc content in food (µg/kg) × food intake (g/day) / 1000)], as previously described13,14. Individual zinc intake was compared to the age- and sex-specific Recommended Dietary Allowance using the DRI Calculator for Healthcare Professionals15. Statistical analysis Data were described as frequencies and percentages for qualitative variables. For quantitative variables, data were presented as mean ± standard deviation or median (interquartile range (IQR)) according to the Kolmogorov–Smirnov normality test. Based on the data type, the relationship between participants’ characteristics and outcomes was investigated using the Pearson Chi-square, Fisher’s Exact, independent t-test, and Mann–Whitney tests. The primary analysis included characteristics of the study’s participants by glycemic status. Then, subgroup analysis included patients with diabetes who were furtherly investigated according to serum zinc levels. Multivariate logistic regression analysis was used to assess factors associated with diabetes prevalence in model 1 and low zinc levels in participants with diabetes mellitus in model 2. However, Firth’s penalized logistic regression was employed to mitigate the quasi-separation in logistic regression model 1.Variables with a p-value ≤ 0.25 in the bivariate analysis were included in the multivariate regression analysis. In model 1 used to assess factors associated with diabetes prevalence, FBS and HbA1C were excluded as they are fundamental components of diabetes diagnosis and monitoring. Multicollinearity between variables was evaluated using the variance inflation factor (VIF). Researchers excluded waist circumference, diastolic blood pressure, creatinine, total cholesterol, and LDL-cholesterol variables from model 1, as they exhibited VIF > 10. However, there were no variables with VIF > 10 in model 2. So, model 1 included age, body mass index, systolic blood pressure, alanine aminotransferase, triglycerides, HDL-cholesterol, serum zinc levels, and dietary zinc intake as independent variables. On the other hand, the explanatory variables in model 2 included gender, waist circumference, HDL-cholesterol, and LDL-cholesterol. R Software and the Statistical Package for the Social Sciences (SPSS, version 28) were used to analyze the data, and statistical significance was set at p < 0.05. Results Characteristics of the study’s participants according to their glycemic status Table 1 shows the characteristics of the study’s participants in relation to the prevalence of diabetes. Of the 195 participants, 51.3% were diabetic (n = 100), while 48.7% were controls (n = 95). There was no significant difference between cases and healthy controls in terms of gender and age. In comparison with the control group, patients with diabetes had a higher median waist circumference (100.0 cm versus 77.5 cm in the control group, p < 0.001). Similarly, cases had a significantly higher median BMI (31.3 kg/m2, IQR 27.4–35.2) compared with the controls, who had a median value of 26.2 kg/m2 (IQR 25.4–28.1), p < 0.001. Although no significant difference was detected between the two groups regarding systolic blood pressure, individuals with diabetes had significantly lower diastolic blood pressure as compared to healthy participants (p = 0.01).Table 1Demographic and clinical characteristics of the study’s subjects.CharacteristicCases (n = 100)Controls (n = 95)P valueDemographics and clinical parametersGender, n (%)0.59 a Male20 (20.0%)22 (23.2%) Female80 (80.0%)73 (76.8%)Age, years48.5 (46.0, 53.0)47.0 (45.0, 51.0)0.10 bBMI, kg/m231.3 (27.4, 35.2)26.2 (25.4, 28.1) < 0.001*bWaist circumference, cm100.0 (93.0,114.0)77.50(75.0,80.0) < 0.001*bSystolic blood pressure, mmHg120.0 (115.0,123.8)120.0(110.0,120.0)0.09 bDiastolic blood pressure, mmHg75.0(70.0,80.0)80.0(75.0,80.0)0.01*bLab parametersFBS, mg/dl178.5 (127.3,225.5)89.0(80.0,95.3) < 0.001*bHbA1C, %8.1 (7.1, 9.4)4.0 (3.2, 4.1) < 0.001*bCreatinine, mg/dl0.8 (0.80, 0.90)0.9 (0.80, 1.0)0.02 *bALT, U/L23.0 (20.0, 25.0)25.0 (23.0, 29.0) < 0.001*bTotal Cholesterol, mg/dL190.0(160.0, 200.0)112.0(110.0, 123.0) < 0.001*bTriglyceride, mg/dL190.0(160.0, 200.0)70.0(65.0, 80.0) < 0.001*bHDL-Cholesterol, mg/dL35.0(32.0, 40.0)50.0(45.0, 52.0) < 0.001*bLDL-cholesterol, mg/dL115.0(109.0, 123.0)98.0(90.0, 100.0) < 0.001*bBMI, body mass index; FBS, Fasting Blood Sugar; HbA1c, Hemoglobin A1c; ALT, alanine aminotransferase.Unless otherwise stated, values were presented as median (IQR).a Pearson Chi-square b Mann–Whitney Test.Bold values with * Indicate statistically significant associations p < 0.05. Table 1Demographic and clinical characteristics of the study’s subjects.CharacteristicCases (n = 100)Controls (n = 95)P valueDemographics and clinical parametersGender, n (%)0.59 a Male20 (20.0%)22 (23.2%) Female80 (80.0%)73 (76.8%)Age, years48.5 (46.0, 53.0)47.0 (45.0, 51.0)0.10 bBMI, kg/m231.3 (27.4, 35.2)26.2 (25.4, 28.1) < 0.001*bWaist circumference, cm100.0 (93.0,114.0)77.50(75.0,80.0) < 0.001*bSystolic blood pressure, mmHg120.0 (115.0,123.8)120.0(110.0,120.0)0.09 bDiastolic blood pressure, mmHg75.0(70.0,80.0)80.0(75.0,80.0)0.01*bLab parametersFBS, mg/dl178.5 (127.3,225.5)89.0(80.0,95.3) < 0.001*bHbA1C, %8.1 (7.1, 9.4)4.0 (3.2, 4.1) < 0.001*bCreatinine, mg/dl0.8 (0.80, 0.90)0.9 (0.80, 1.0)0.02 *bALT, U/L23.0 (20.0, 25.0)25.0 (23.0, 29.0) < 0.001*bTotal Cholesterol, mg/dL190.0(160.0, 200.0)112.0(110.0, 123.0) < 0.001*bTriglyceride, mg/dL190.0(160.0, 200.0)70.0(65.0, 80.0) < 0.001*bHDL-Cholesterol, mg/dL35.0(32.0, 40.0)50.0(45.0, 52.0) < 0.001*bLDL-cholesterol, mg/dL115.0(109.0, 123.0)98.0(90.0, 100.0) < 0.001*bBMI, body mass index; FBS, Fasting Blood Sugar; HbA1c, Hemoglobin A1c; ALT, alanine aminotransferase.Unless otherwise stated, values were presented as median (IQR).a Pearson Chi-square b Mann–Whitney Test.Bold values with * Indicate statistically significant associations p < 0.05. Demographic and clinical characteristics of the study’s subjects. 77.50 (75.0,80.0) 120.0 (110.0,120.0) 75.0 (70.0,80.0) 80.0 (75.0,80.0) 89.0 (80.0,95.3) 190.0 (160.0, 200.0) 112.0 (110.0, 123.0) 190.0 (160.0, 200.0) 70.0 (65.0, 80.0) 35.0 (32.0, 40.0) 50.0 (45.0, 52.0) 115.0 (109.0, 123.0) 98.0 (90.0, 100.0) BMI, body mass index; FBS, Fasting Blood Sugar; HbA1c, Hemoglobin A1c; ALT, alanine aminotransferase. Unless otherwise stated, values were presented as median (IQR). a Pearson Chi-square b Mann–Whitney Test. Bold values with * Indicate statistically significant associations p < 0.05. The diabetic group had significantly higher median fasting blood sugar and HbA1C than the healthy group (p < 0.001). Total Cholesterol (TC), Triglyceride (TG), and LDL-cholesterol were all significantly increased in patients with diabetes, while HDL-Cholesterol, creatinine, and alanine aminotransferase (ALT) were significantly decreased in patients with diabetes as compared to healthy controls (Creatinine: p = 0.02; all other tests: p < 0.001). Serum zinc level and dietary zinc intake in diabetic cases and healthy controls The differences in serum zinc levels and daily dietary zinc intake between patients with T2D and controls are presented in Fig. 1. Significantly higher median serum zinc levels were found in healthy participants compared to the diabetic group, with a median of 99.0 μg/dL (IQR 84.0–111.0) versus 64.5 μg/dL (IQR 57.0–67.0) (p < 0.001). However, results indicated no significant difference in the median daily dietary zinc intake between the two groups (p = 0.21).Fig. 1Difference in serum zinc levels and daily dietary zinc intake between cases with diabetes and healthy controls. Data are displayed as boxplots, with the lower and upper box limits representing the first and third quartiles, and the center line defining the median. Vertical extending lines represent minimum and maximum values within 1.5 × IQR beyond the edges of the box, and Dots indicate outliers. Difference in serum zinc levels and daily dietary zinc intake between cases with diabetes and healthy controls. Data are displayed as boxplots, with the lower and upper box limits representing the first and third quartiles, and the center line defining the median. Vertical extending lines represent minimum and maximum values within 1.5 × IQR beyond the edges of the box, and Dots indicate outliers. Multivariate Firth’s penalized logistic regression analysis of the factors associated with diabetes mellitus prevalence Multivariate Firth’s penalized logistic regression model was employed to assess factors associated with diabetes prevalence (Fig. 2). Interestingly, analysis has indicated that each one-unit increase in serum zinc level was associated with 6% lower odds of diabetes prevalence (OR = 0.94, 95% CI = 0.88–0.98, p = 0.007) (Fig. 2). Dietary zinc intake wasn’t significantly associated with diabetes prevalence. On the other hand, HDL-Cholesterol was negatively associated with diabetes prevalence (OR = 0.80, 95% CI 0.64–0.94, p = 0.007), while triglyceride was positively associated with diabetes prevalence (OR = 1.04, 95% CI 1.02–1.07, p < 0.001). However, the prevalence of diabetes mellitus did not significantly differ according to participants’ age, BMI, ALT level, or systolic blood pressure.Fig. 2Multivariate Firth’s Penalized Logistic Regression Analysis of the Participants’ Characteristics Related to Diabetes Mellitus Prevalence. Values beside each point estimate indicate odds ratio (95% CI). indicate adjusted Odds ratio (95% CI). The model was adjusted to age, BMI, systolic blood pressure, ALT, triglyceride, HDL-cholesterol, serum zinc levels, and dietary zinc intake as independent variables. * Indicate statistically significant associations p < 0.05. CI confidence interval, BMI body mass index, ALT alanine aminotransferase. Multivariate Firth’s Penalized Logistic Regression Analysis of the Participants’ Characteristics Related to Diabetes Mellitus Prevalence. Values beside each point estimate indicate odds ratio (95% CI). indicate adjusted Odds ratio (95% CI). The model was adjusted to age, BMI, systolic blood pressure, ALT, triglyceride, HDL-cholesterol, serum zinc levels, and dietary zinc intake as independent variables. * Indicate statistically significant associations p < 0.05. CI confidence interval, BMI body mass index, ALT alanine aminotransferase. Sources of dietary zinc in the study participants Figure 3 illustrates the contributions of the main food groups to dietary zinc intake in the study’s participants. Data demonstrated that more than three-quarters of the daily zinc intake was derived from protein, vegetables, and bread/grain products (30.5%, 24.6%, and 24.3% respectively). The contribution rates of milk/dairy and fruit/nut products were 13.0% and 6.8%, respectively. The absolute amounts of dietary zinc derived from each dietary source (in mg/day) are presented in Table 2.Fig. 3The dietary sources of zinc in the study participants.Table 2Zinc amount derived from various dietary sources in participants with and without diabetes mellitus.Food groupsCases a(n = 100)Controls a(n = 95)P valueProtein2.9 (1.9, 4.3)2.1 (1.5, 2.9)0.001*Milk and Dairy1.3 (0.9, 1.7)0.6 (0.1, 1.4) < 0.001*Bread and grain1.3 (0.9, 2.5)2.5 (1.3, 3.2)0.01 *Vegetables1.6 (1.2, 2.5)2.1 (1.6, 2.6)0.002 *Fat0.03 (0.01, 0.2)0.03 (0.03, 0.1)0.98Fruits and nuts0.3 (0.1, 0.97)0.2 (0.1, 1.0)0.53a Zinc amount derived from each food group in mg/day.Values were presented as median (IQR).Bold values with * Indicate statistically significant associations p < 0.05. The dietary sources of zinc in the study participants. Table 2Zinc amount derived from various dietary sources in participants with and without diabetes mellitus.Food groupsCases a(n = 100)Controls a(n = 95)P valueProtein2.9 (1.9, 4.3)2.1 (1.5, 2.9)0.001*Milk and Dairy1.3 (0.9, 1.7)0.6 (0.1, 1.4) < 0.001*Bread and grain1.3 (0.9, 2.5)2.5 (1.3, 3.2)0.01 *Vegetables1.6 (1.2, 2.5)2.1 (1.6, 2.6)0.002 *Fat0.03 (0.01, 0.2)0.03 (0.03, 0.1)0.98Fruits and nuts0.3 (0.1, 0.97)0.2 (0.1, 1.0)0.53a Zinc amount derived from each food group in mg/day.Values were presented as median (IQR).Bold values with * Indicate statistically significant associations p < 0.05. Zinc amount derived from various dietary sources in participants with and without diabetes mellitus. a Zinc amount derived from each food group in mg/day. Values were presented as median (IQR). Bold values with * Indicate statistically significant associations p < 0.05. Association between zinc derived from various dietary sources and diabetes prevalence Compared to controls, participants with diabetes received significantly higher quantities of zinc from animal-based sources such as protein foods and dairy products (p = 0.001, < 0.001, respectively) (Table 2). Controls obtained significantly more zinc from plant-based sources than cases, including bread, grains, and vegetables (p = 0.01, 0.002, respectively). Zinc-based subgroup analysis in participants with diabetes Patients with diabetes were categorized based on serum zinc levels of 65 µg/dl to normal zinc and low zinc groups16. Results illustrated that there was a zinc deficiency in 50% of diabetes patients (Table 3). As compared to the normal zinc group, females were more prevalent in the low zinc group (66.0%) versus 94.0%, p < 0.001). There was no significant statistical difference between the two groups regarding the duration of diabetes or treatment (p = 0.72, 0.53, respectively). There was no significant statistical difference between the Zn-deficient and normal Zn groups in terms of various laboratory parameters, including glycemic control, lipid profile, renal function, and hepatic status tests.Table 3Characteristics of participants with diabetes categorized by serum zinc level.CharacteristicNormal zinc(n = 50)Low zinc(n = 50)P valueDemographics and clinical parametersGender, n (%) < 0.001 *a Male17 (34.0)3 (6.0) Female33 (66.0)47 (94.0)Age, years48.0 (45.0, 53.3)49.0 (46.0, 53.0)0.52 cBMI, kg/m2 mean ± SD32.0 ± 6.031.0 ± 5.20.51 dWaist circumference, cm101.0(93.8, 118.5)100.0(90.0, 110.5)0.25 cSystolic blood pressure, mmHg120.0(115.0, 125.0)120.0(115.0, 121.3)0.55 cDiastolic blood pressure, mmHg75.5 (70.0, 80.0)75.0 (70.0, 80.0)0.90 cDiabetes duration6.0 (4.8, 8.0)5.5 (4.0, 8.0)0.72 cDiabetes treatment0.53 a Oral glucose-lowering medications32 (64.0)28 (56.0) Insulin12 (24.0)12 (24.0) Oral medications + insulin6 (12.0)10 (20.0)Lab parametersFBS, mg/dl mean ± SD182.9 ± 69.7186.7 ± 68.90.78 dHbA1C, %8.0 (7.0, 9.5)8.20 (7.1, 9.0)0.88 cCreatinine, mg/dl0.80 (0.8, 0.9)0.80 (0.7, 0.9)0.75 cALT, U/L23.0 (20.0, 25.0)23.0 (20.8, 25.0)0.84 cTotal Cholesterol, mg/dL190.0(157.0, 206.5)188.50(160.0, 200.0)0.68 cTriglyceride, mg/dL190.0(156.0, 203.5)190.0(167.0, 202.5)0.69 cHDL-Cholesterol, mg/dL35.0 (30.8, 40.0)36.0 (32.8, 40.0)0.22 cLDL-cholesterol, mg/dL113.0(105.0, 123.0)120.0(110.0, 123.50)0.21 cBMI body mass index, FBS Fasting Blood Sugar, HbA1c Hemoglobin A1c, ALT alanine aminotransferase.Unless otherwise stated, values were presented as median (IQR).a Pearson Chi-square b Fisher’s Exact Test c Mann–Whitney Test d independent samples t test.Bold values with * Indicate statistically significant associations p < 0.05. Table 3Characteristics of participants with diabetes categorized by serum zinc level.CharacteristicNormal zinc(n = 50)Low zinc(n = 50)P valueDemographics and clinical parametersGender, n (%) < 0.001 *a Male17 (34.0)3 (6.0) Female33 (66.0)47 (94.0)Age, years48.0 (45.0, 53.3)49.0 (46.0, 53.0)0.52 cBMI, kg/m2 mean ± SD32.0 ± 6.031.0 ± 5.20.51 dWaist circumference, cm101.0(93.8, 118.5)100.0(90.0, 110.5)0.25 cSystolic blood pressure, mmHg120.0(115.0, 125.0)120.0(115.0, 121.3)0.55 cDiastolic blood pressure, mmHg75.5 (70.0, 80.0)75.0 (70.0, 80.0)0.90 cDiabetes duration6.0 (4.8, 8.0)5.5 (4.0, 8.0)0.72 cDiabetes treatment0.53 a Oral glucose-lowering medications32 (64.0)28 (56.0) Insulin12 (24.0)12 (24.0) Oral medications + insulin6 (12.0)10 (20.0)Lab parametersFBS, mg/dl mean ± SD182.9 ± 69.7186.7 ± 68.90.78 dHbA1C, %8.0 (7.0, 9.5)8.20 (7.1, 9.0)0.88 cCreatinine, mg/dl0.80 (0.8, 0.9)0.80 (0.7, 0.9)0.75 cALT, U/L23.0 (20.0, 25.0)23.0 (20.8, 25.0)0.84 cTotal Cholesterol, mg/dL190.0(157.0, 206.5)188.50(160.0, 200.0)0.68 cTriglyceride, mg/dL190.0(156.0, 203.5)190.0(167.0, 202.5)0.69 cHDL-Cholesterol, mg/dL35.0 (30.8, 40.0)36.0 (32.8, 40.0)0.22 cLDL-cholesterol, mg/dL113.0(105.0, 123.0)120.0(110.0, 123.50)0.21 cBMI body mass index, FBS Fasting Blood Sugar, HbA1c Hemoglobin A1c, ALT alanine aminotransferase.Unless otherwise stated, values were presented as median (IQR).a Pearson Chi-square b Fisher’s Exact Test c Mann–Whitney Test d independent samples t test.Bold values with * Indicate statistically significant associations p < 0.05. Characteristics of participants with diabetes categorized by serum zinc level. 101.0 (93.8, 118.5) 100.0 (90.0, 110.5) 120.0 (115.0, 125.0) 120.0 (115.0, 121.3) 190.0 (157.0, 206.5) 188.50 (160.0, 200.0) 190.0 (156.0, 203.5) 190.0 (167.0, 202.5) 113.0 (105.0, 123.0) 120.0 (110.0, 123.50) BMI body mass index, FBS Fasting Blood Sugar, HbA1c Hemoglobin A1c, ALT alanine aminotransferase. Unless otherwise stated, values were presented as median (IQR). a Pearson Chi-square b Fisher’s Exact Test c Mann–Whitney Test d independent samples t test. Bold values with * Indicate statistically significant associations p < 0.05. Factors associated with serum zinc level in patients with diabetes mellitus A multivariate logistic regression model was used to assess the factors related to serum zinc deficiency in patients with diabetes (Fig. 4). Males had 90% lower odds of low serum zinc than females (OR 0.1, 95% CI 0.03–0.40; p = 0.001). Although HDL-cholesterol wasn’t significantly associated with zinc deficiency, each 1 mg/dL increase in LDL-cholesterol increased the odds of outcome by 4% (OR = 1.04, 95% CI 1.004–1.07, p = 0.03). Waist circumference was not significantly related to zinc deficiency in the multivariate regression model.Fig. 4A multivariate logistic regression model of the factors associated with serum zinc deficiency in participants with diabetes mellitus. Values beside each point estimate indicate odds ratio (95% CI). The model was adjusted for gender, waist circumference, HDL-cholesterol, and LDL-cholesterol.CI, confidence interval. * Indicate statistically significant associations p < 0.05. A multivariate logistic regression model of the factors associated with serum zinc deficiency in participants with diabetes mellitus. Values beside each point estimate indicate odds ratio (95% CI). The model was adjusted for gender, waist circumference, HDL-cholesterol, and LDL-cholesterol.CI, confidence interval. * Indicate statistically significant associations p < 0.05. Discussion To the best of our knowledge, this is the first study conducted in Egypt to compare dietary zinc intake and serum zinc levels, and to examine their association with diabetes prevalence. Our study identified significant differences in the physical and cardiovascular profiles of diabetic patients compared to healthy controls. Individuals with T2D demonstrated a greater prevalence of central obesity, as evidenced by higher weight, Body Mass Index (BMI), and waist circumference. Even so, the diabetic group demonstrated a significantly lower diastolic blood pressure (DBP) compared to the non-diabetic group. Importantly, since all patients receiving antihypertensive agents were excluded from the study, the observed DBP difference reflects untreated hemodynamic values and cannot be attributed to any pharmacological effect. This finding is consistent with well-established evidence that T2D is associated with distinct vascular hemodynamic alterations independent of treatment. The precise pathological mechanisms underlying vascular alterations in T2D remain under investigation; however, increased arterial stiffness and reduced vascular compliance may be a mechanistic link between the diabetic vascular state and reduced DBP. Indeed, arterial stiffness can cause premature wave reflection that increases mid-to-late systolic load while lowering DBP. This hemodynamic remodeling characterized by elevated SBP alongside reduced DBP is a hallmark of the widened pulse pressure that accompanies progressive loss of arterial compliance in diabetes17–19. Nevertheless, serum zinc levels were found to be significantly lower in diabetic patients compared to healthy controls. This difference persisted even though dietary zinc intake was comparable between the two groups, suggesting a possible association with altered zinc absorption or metabolism in the diabetic state, though this cannot be confirmed from cross-sectional data. Despite that our findings showed that dietary zinc intake wasn’t significantly associated with diabetes prevalence. After adjusting for confounding variables, a powerful association emerged where each one-unit increase in serum zinc level was associated with 6% lower odds of diabetes prevalence (OR = 0.94, 95% CI = 0.88–0.98, p = 0.007). This finding is clinically relevant, as typical healthy serum zinc concentrations range from 80 to 120 mcg/dL. Levels below 70–74 mcg/dL are considered deficient20. The reduced zinc concentration in diabetics may therefore represent a state of functional deficiency that is associated with the pathophysiology of the disease, though the direction of this relationship cannot be determined from the present study design. The relationship between zinc and glucose metabolism is, however, complex and not without controversy in the existing literature. While some research supports our finding of an association between lower zinc levels and glucose intolerance or insulin resistance, other studies present a conflicting view21. Pro-Deficiency Hypothesis: several studies have suggested that low zinc levels impair insulin synthesis, storage, and secretion, thereby contributing to the development of diabetes and related cardiovascular diseases22,23. Pro-Excess Hypothesis: conversely, other investigations have linked higher serum zinc levels with adverse effect on glucose metabolism and an increased risk of metabolic syndrome24. Elevated zinc has been observed in prediabetic individuals and high insulin level was associated with increased insulin resistance as measured by HOMA-IR25. Moreover, studies indicate that excessive zinc exposure can be toxic to pancreatic beta cells and exacerbates their death in response to different stressors26. In consistency, a study revealed a positive association between serum zinc and HOMA-IR (a marker of insulin resistance) in patients with metabolic syndrome27. On the other hand, another study in Lebanese adults found no significant link between zinc levels and metabolic syndrome28. This body of conflicting evidence suggests that the role of zinc is likely context-dependent, possibly following a U-shaped curve where both deficiency and excess are detrimental. In agreement, a study has reported a strong association between serum zinc and insulin resistance that is largely influenced by age24. The reduced zinc levels observed in our diabetic cohort could be a compensatory mechanism to mitigate potential zinc-induced toxicity or, alternatively, a factor associated with the disease; however, the present cross-sectional design does not permit causal conclusions. Moreover, although participants with diabetes consumed significantly higher amounts of zinc from animal-based sources, including protein foods and dairy products (p = 0.001 and p < 0.001, respectively), the control group obtained significantly greater amounts of zinc from plant-based sources such as bread, grains, and vegetables (p = 0.01 and p = 0.002, respectively). Despite the theoretically higher bioavailability of zinc from animal sources, zinc status remained deficient among individuals with diabetes. This finding highlights the need for further human studies focusing on individuals with diabetes, as altered mineral absorption and metabolism may influence zinc bioavailability differently in this population29. In the present study, HDL-cholesterol (HDL-C) demonstrated a significant inverse association with diabetes prevalence, whereas triglyceride concentrations were positively associated with diabetes prevalence. Specifically, higher HDL-C levels were associated with a reduced likelihood of diabetes (OR = 0.80, 95% CI: 0.64–0.94, p = 0.007), while increasing triglyceride levels were linked to a greater prevalence of diabetes (OR = 1.04, 95% CI: 1.02–1.07, p < 0.001). Conversely, no statistically significant associations were identified between diabetes prevalence and age, body mass index (BMI), alanine aminotransferase (ALT) levels, or systolic blood pressure. The observed inverse relationship between HDL-C and diabetes prevalence is consistent with previous epidemiological and experimental findings. Lee et al.30 reported that reduced HDL-C concentrations were independently associated with an elevated risk of future diabetes development. Likewise, a retrospective cohort study conducted among a Japanese population demonstrated that lower HDL-C levels significantly increased the risk of incident diabetes mellitus31. Experimental evidence further supports the protective role of HDL against diabetes through multiple mechanisms, including the prevention of pancreatic β-cell apoptosis, enhancement of glucose-stimulated insulin secretion, and promotion of glucose uptake in peripheral tissues32,33. Additionally, apolipoprotein A-I, the principal structural protein of HDL particles, has been shown to enhance insulin secretion34. Nevertheless, findings from a Mendelian randomization study indicated that genetically determined reductions in HDL-C levels were not significantly associated with the risk of type 2 diabetes mellitus (T2DM), suggesting that the observed epidemiological association may partially reflect shared metabolic determinants rather than a direct causal effect35. The positive association between triglyceride concentrations and diabetes prevalence observed in this study is similarly supported by previous research. Rial et al. described several biological mechanisms through which triglyceride accumulation contributes to insulin resistance, β-cell dysfunction, impaired glucose metabolism, and increased hepatic glucose production36. Furthermore, elevated circulating free fatty acids derived from triglycerides may exacerbate insulin resistance, thereby perpetuating a vicious cycle of hypertriglyceridemia and impaired insulin sensitivity37. A prospective study also demonstrated that persistently elevated triglyceride levels independently predicted the development of T2DM37. Moreover, triglyceride deposition within hepatic and skeletal muscle tissues has been associated with impaired insulin signaling pathways and reduced glucose uptake38. The triglyceride-glucose (TyG) index and the triglyceride-to-HDL-C (TG/HDL-C) ratio have likewise been recognized as reliable surrogate markers of insulin resistance and predictors of future T2DM risk39,40. The coexistence of elevated triglyceride levels and reduced HDL-C concentrations, characteristic of atherogenic dyslipidemia, further underscores the clinical relevance of lipid abnormalities in diabetes risk stratification. Collectively, these findings support the incorporation of comprehensive lipid profile assessment into routine metabolic screening practices. In contrast, no significant associations were detected between diabetes prevalence and age, BMI, ALT levels, or systolic blood pressure. Although elevated systolic blood pressure has been linked to an increased risk of diabetes in previous investigations41, this relationship may be attenuated by factors such as advancing age and increased BMI, potentially explaining the lack of significance observed in the present study. Similarly, while elevated ALT concentrations have been associated with metabolic syndrome and T2DM in some studies42, other reports suggest that this relationship may vary according to population characteristics and the extent of adjustment for confounding variables43. Furthermore, the absence of significant associations for BMI and age may be attributable to collinearity among metabolic risk factors, specific characteristics of the study population, and the inherent limitations of the cross-sectional study design, which may obscure the independent effects of these variables on diabetes prevalence. Compared with participants exhibiting normal serum zinc concentrations, females were significantly overrepresented among individuals with low serum zinc levels (66.0% vs. 94.0%, p < 0.001). In addition, males exhibited approximately 90% lower odds of zinc deficiency compared with females (OR = 0.10, 95% CI: 0.03–0.40, p = 0.001). These findings contrast with those reported by another study, which observed a higher prevalence of zinc deficiency among males44. Nevertheless, zinc bioavailability is influenced by multiple physiological and environmental factors beyond sex alone, which may contribute to these discrepancies45. Although HDL-C concentrations were not significantly associated with the prevalence of zinc deficiency, each 1 mg/dL increase in LDL-cholesterol was associated with a 4% increase in the odds of zinc deficiency (OR = 1.04, 95% CI: 1.00–1.07, p = 0.03). Consistent with these findings, a recent study suggested that zinc supplementation may represent an effective strategy for improving lipid profiles and body composition among individuals with T2DM46. The beneficial effects of zinc on lipid metabolism are thought to be mediated, at least in part, through its insulin-mimetic actions, which facilitate lipid transport and storage within adipose tissue and contribute to improved lipid homeostasis47. Limitations We acknowledge several limitations associated with zinc measurement in both serum and plasma. Although all samples in our study were collected in the morning to minimize diurnal variation, serum zinc levels remain influenced by factors such as sex and age, and they may not reliably reflect dietary or supplemental zinc intake. Moreover, zinc concentrations can be affected by physiological and pathological conditions, including infections, hormonal fluctuations, and muscle catabolism during weight loss or illness. These variables were not accounted for in our analysis. Additionally, total energy intake was not assessed alongside dietary zinc, which limits interpretation of nutrient density. These limitations should be considered when interpreting the findings. Conclusion Collectively, these cross-sectional findings indicate that individuals with diabetes exhibited significantly lower serum zinc concentrations despite comparable dietary zinc intake, while higher serum zinc levels were associated with markedly reduced odds of diabetes. In addition, significant differences in diastolic blood pressure and lipid profiles were observed between the study groups. Given the observational nature of this study, causal inferences cannot be drawn; however, the consistent presence of zinc deficiency among individuals with diabetes warrants further investigation. Future prospective and interventional studies should focus on determining optimal zinc formulations and establishing evidence-based dosing strategies to evaluate whether zinc supplementation may offer metabolic and cardiovascular benefits.